Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
John Francis Seymour
Consultant or Advisory Role - Genentech
Research Funding - AbbVie; Genentech
Matthew Steven Davids
No relevant relationships to disclose
John M. Pagel
No relevant relationships to disclose
Brad S. Kahl
Consultant or Advisory Role - Genentech
Research Funding - AbbVie; Genentech
William G. Wierda
Consultant or Advisory Role - Genentech
Research Funding - AbbVie; Genentech
Thomas P. Miller
No relevant relationships to disclose
John F. Gerecitano
Research Funding - AbbVie; Genentech
Thomas J. Kipps
Research Funding - AbbVie
Mary Ann Anderson
Research Funding - AbbVie; Genentech
David C.S. Huang
Stock Ownership - AbbVie
Research Funding - AbbVie; Genentech
David E. Darden
Research Funding - AbbVie; Genentech
Lori A. Gressick
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Cathy E. Nolan
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Jianning Yang
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Todd A. Busman
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Alison M. Graham
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Elisa Cerri
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Sari H. Enschede
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Rod A. Humerickhouse
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Andrew Warwick Roberts
Research Funding - AbbVie; Genentech